Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Myeloid 1

Conditions

Carcinoma, Hepatocellular 22Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 9Nasopharyngeal Carcinoma 5Lung Neoplasms 5Esophageal Squamous Cell Carcinoma 5Small Cell Lung Carcinoma 4Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma 3Nonsquamous Non-Small Cell Lung Cancer 2Nasopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Advanced Biliary Tract Cancer 2Unresectable Locally Advanced Pancreatic Cancer 1Triple Negative Breast Neoplasms 1Tislelizumab 1Thoracic Neoplasms 1Thoracic Malignancies 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Respiratory Tract Diseases 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1

Interventions

pegaspargase 14Etoposide 11Dexamethasone 11Gemcitabine 10spartalizumab 6Oxaliplatin 4sintilimab 3Radiotherapy 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methotrexate 3Asparaginase 3tislelizumab 2camrelizumab 2Lenalidomide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2Busulfan 2Azacitidine 2toripalimab 1tofacitinib 1ruxolitinib 1romidepsin 1pembrolizumab 1fludarabine phosphate 1avelumab 1apatinib 1Thalidomide 1Sensitivity and Specificity 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Extranodal NK-T-Cell × sintilimab × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04676789 2020-12-21

SPENT

Sun Yat-sen University

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡